Ahmed M. Nabeel

Ahmed M. Nabeel

Auto-generated profile, based on publicly available information

Ahmed M. Nabeel

Gamma Knife Center Cairo, Nasser Institute Hospital, Cairo, Egypt

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 August 2017 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
PDF file
GMGautam U Mehta
Gautam U Mehta
DDDale Ding
Dale Ding
MPMohana Rao Patibandla
Mohana Rao Patibandla
HKHideyuki Kano
Hideyuki Kano
NSNathaniel Sisterson
Nathaniel Sisterson
JSJason P. Sheehan
Jason P. Sheehan
Context Cushing’s disease (CD) due to ACTH-secreting pituitary tumors can be a management challenge. Objective To better understand the outcomes of stereotactic radiosurgery (SRS) for CD and define its role in management. Design International, multicenter, retrospective cohort analysis. Setting Ten medical centers participating in the International Gamma Knife Research Foundation (IGKRF). Patients Patients with CD with greater than 6 months endocrine follow-up. Intervention SRS using Gamma Knife radiosurgery. Main outcome measures The primary outcome was control of hypercortisolism (defined as normalization of free urinary cortisol). Radiologic response and adverse radiation effects were recorded. Results 278 patients met inclusion criteria, with mean follow-up of 5.6 years (0.5-20.5 years). Twenty-two patients received SRS as a primary treatment for CD. Mean margin dose was 23.7 Gy. Cumulative initial control of hypercortisolism was 80% at 10 years. Mean time to cortisol normalization was 14.5 months. Recurrences occurred in 18% with initial cortisol normalization. Overall, the rate of durable control of hypercortisolism was 64% at 10 years, and 68% among patients who received SRS as a primary treatment. Adverse radiation effects included hypopituitarism (25%) and cranial neuropathy (3%). Visual deficits were related to treatment of tumor within the suprasellar cistern (P=0.01), while both visual (P<0.0001) and non-visual cranial neuropathy (P=0.02) were related to prior pituitary irradiation. Conclusions SRS for CD is well-tolerated and frequently results in control of hypercortisolism. However, recurrences can occur. SRS should be considered for patients with persistent hypercortisolism after pituitary surgery and as a primary treatment in those unfit for surgery. Long-term endocrine follow-up is essential after SRS.

2 March 2023 in Neurosurgery
Verified
Journal Article
Open access
OBOthman Bin-Alamer
Othman Bin-Alamer
AFAndrew Faramand
Andrew Faramand
NANorah A. Alarifi
Norah A. Alarifi
ZWZhishuo Wei
Zhishuo Wei
AMArka N. Mallela
Arka N. Mallela
HAHussam Abou-Al-Shaar
Hussam Abou-Al-Shaar
BACKGROUND: Vestibular schwannomas (VSs) related to neurofibromatosis type 2 (NF2) are challenging tumors. The increasing use of stereotactic radiosurgery (SRS) necessitates further investigations of its role and safety. OBJECTIVE: To evaluate tumor control, freedom from additional treatment (FFAT), serviceable hearing preservation, and radiation-related risks of patients with NF2 after SRS for VS. METHODS: We performed a retrospective study of 267 patients with NF2 (328 VSs) who underwent single-session SRS at 12 centers participating in the International Radiosurgery Research Foundation. The median patient age was 31 years (IQR, 21-45 years), and 52% were male. RESULTS: A total of 328 tumors underwent SRS during a median follow-up time of 59 months (IQR, 23-112 months). At 10 and 15 years, the tumor control rates were 77% (95% CI: 69%-84%) and 52% (95% CI: 40%-64%), respectively, and the FFAT rate were 85% (95% CI: 79%-90%) and 75% (95% CI: 65%-86%), respectively. At 5 and 10 years, the serviceable hearing preservation rates were 64% (95% CI: 55%-75%) and 35% (95% CI: 25%-54%), respectively. In the multivariate analysis, age (hazards ratio: 1.03 [95% CI: 1.01-1.05]; P = .02) and bilateral VSs (hazards ratio: 4.56 [95% CI: 1.05-19.78]; P = .04) were predictors for serviceable hearing loss. Neither radiation-induced tumors nor malignant transformation were encountered in this cohort. CONCLUSION: Although the absolute volumetric tumor progression rate was 48% at 15 years, the rate of FFAT related to VS was 75% at 15 years after SRS. None of the patients with NF2-related VS developed a new radiation-related neoplasm or malignant transformation after SRS.

1 August 2018 in World Neurosurgery
Verified
Journal Article
Closed access
MSMatthew J. Shepard
Matthew J. Shepard
GMGautam U. Mehta
Gautam U. Mehta
ZXZhiyuan Xu
Zhiyuan Xu
HKHideyuki Kano
Hideyuki Kano
NSNathaniel Sisterson
Nathaniel Sisterson
JSJason P. Sheehan
Jason P. Sheehan

1 December 2016 in Journal of Neurosurgery
Verified
Journal Article
Closed access
AEAmr El-Shehaby
Amr El-Shehaby
WRWael A. Reda
Wael A. Reda
KKKhaled M. Abdel Karim
Khaled M. Abdel Karim
REReem M. Emad Eldin
Reem M. Emad Eldin
ANAhmed M. Nabeel
Ahmed M. Nabeel
OBJECTIVE: Because of their critical and central location, it is deemed necessary to fractionate when considering irradiating optic pathway/hypothalamic gliomas. Stereotactic fractionated radiotherapy is considered safer when dealing with gliomas in this location. In this study, the safety and efficacy of single-session stereotactic radiosurgery for optic pathway/hypothalamic gliomas were reviewed.METHODS: Between December 2004 and June 2014, 22 patients with optic pathway/hypothalamic gliomas were treated by single-session Gamma Knife radiosurgery. Twenty patients were available for follow-up for a minimum of 1 year after treatment. The patients were 5 to 43 years (median 16 years) of age. The tumor volume was 0.15 to 18.2 cm3 (median 3.1 cm3). The prescription dose ranged from 8 to 14 Gy (median 11.5 Gy).RESULTS: The mean follow-up period was 43 months. Five tumors involved the optic nerve only, and 15 tumors involved the chiasm/hypothalamus. Two patients died during the follow-up period. The tumors shrank in 12 cases, remained stable in 6 cases, and progressed in 2 cases, thereby making the tumor control rate 90%. Vision remained stable in 12 cases, improved in 6 cases, and worsened in 2 cases in which there was tumor progression. Progression-free survival was 83% at 3 years.CONCLUSIONS: The initial results indicate that single-session Gamma Knife radiosurgery is a safe and effective treatment option for optic pathway/hypothalamic gliomas.

1 August 2023 in Stroke
Verified
Journal Article
Closed access
GMGeorgios Mantziaris
Georgios Mantziaris
SPStylianos Pikis
Stylianos Pikis
CDChloe Dumot
Chloe Dumot
SDSamantha Dayawansa
Samantha Dayawansa
RLRoman Liščák
Roman Liščák
JSJason P. Sheehan
Jason P. Sheehan
BACKGROUND: Repeat stereotactic radiosurgery (SRS) for persistent cerebral arteriovenous malformation (AVM) has generally favorable patient outcomes. However, reporting studies are limited by small patient numbers and single-institution biases. The purpose of this study was to provide the combined experience of multiple centers, in an effort to fully define the role of repeat SRS for patients with arteriovenous malformation. METHODS: This multicenter, retrospective cohort study included patients treated with repeat, single-fraction SRS between 1987 and 2022. Follow-up began at repeat SRS. The primary outcome was a favorable patient outcome, defined as a composite of nidus obliteration in the absence of hemorrhage or radiation-induced neurological deterioration. Secondary outcomes were obliteration, hemorrhage risk, and symptomatic radiation-induced changes. Competing risk analysis was performed to compute yearly rates and identify predictors for each outcome. RESULTS: The cohort comprised 505 patients (254 [50.3%] males; median [interquartile range] age, 34 [15] years) from 14 centers. The median clinical and magnetic resonance imaging follow-up was 52 (interquartile range, 61) and 47 (interquartile range, 52) months, respectively. At last follow-up, favorable outcome was achieved by 268 (53.1%) patients (5-year probability, 50% [95% CI, 45%–55%]) and obliteration by 300 (59.4%) patients (5-year probability, 56% [95% CI, 51%–61%]). Twenty-eight patients (5.6%) experienced post-SRS hemorrhage with an annual incidence rate of 1.38 per 100 patient-years. Symptomatic radiation-induced changes were evident in 28 (5.6%) patients, with most occurring in the first 3 years. Larger nidus volumes (between 2 and 4 cm 3 , subdistribution hazard, 0.61 [95% CI, 0.44–0.86]; P =0.005; >4 cm 3 , subdistribution hazard, 0.47 [95% CI, 0.32–0.7]; P <0.001) and brainstem/basal ganglia involvement (subdistribution hazard, 0.6 [95% CI, 0.45–0.81]; P <0.001) were associated with reduced probability of favorable outcome. CONCLUSIONS: Repeat SRS confers reasonable obliteration rates with a low complication risk. With most complications occurring in the first 3 years, extending the latency period to 5 years generally increases the rate of favorable patient outcomes and reduces the necessity of a third intervention.

1 December 2019 in World Neurosurgery
Verified
Journal Article
Closed access
AEAmr El-Shehaby
Amr El-Shehaby
WRWael A. Reda
Wael A. Reda
KKKhaled M. Abdel Karim
Khaled M. Abdel Karim
REReem M. Emad Eldin
Reem M. Emad Eldin
ANAhmed M. Nabeel
Ahmed M. Nabeel
STSameh R. Tawadros
Sameh R. Tawadros